Feto-maternal microchimerism suggests immunological tolerance between mother and fetus.
Introduction
The cure for thalassemia involves correcting the genetic defect in a hematopoietic stem cell that results in reduced or absent β -globin synthesis and an excess of α -globin dimers.
Intracellular precipitation and accumulation of α -dimers results in ineffective erythropoiesis and hemolytic anemia. Replacing the abnormal thalassemic marrow with allogeneic normal or heterozygous stem cells carrying the functional gene restores appropriate β -globin chain synthesis. Eighty to ninety per cent of patients transplanted from an HLA-identical sibling or parent become ex-thalassemic after transplant 1, 2 .
In the multiracial populations from the Mediterranean region, Middle East, and Arabian
Gulf, the probability of having an HLA-identical related donor is 35-40%. Thus, the pool of potential donors must be expanded in order to cure most children with thalassemia or sickle cell anemia. The outcomes following HLA-matched unrelated donor transplant for treating thalassemia are comparable to those following HLA-identical familial transplant 3 . The use of mismatched, unrelated cord blood hematopoietic stem cells is still experimental.
Haploidentical hemopoietic stem cell transplantation has been explored as an option for treating patients with leukemia who lack an HLA-identical sibling or parent donor. However, severe graft versus host disease (GVHD) and high graft failure/rejection rates have limited the application of this transplant modality for patients with thalassemia. Advances using high doses of T cell-depleted peripheral blood stem cells (PBSCs) and intensive pre-transplant conditioning regimens have helped to overcome these limitations 4 . Grafts containing mega doses of enriched CD34 + progenitor cells can be achieved by combining bone marrow with G-CSF-mobilized PBSCs. Thereafter, T-cells can be removed by positive selection for CD34.
Limiting the numbers of CD3 + cells in the graft might allow retention of rapid engraftment kinetics provided by the mobilized PBSCs while reducing the risk of extensive GVHD. In
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Patients and methods

During
and a completely unsatisfactory one by 100%. 6 Patient characteristics are presented in Table 1 .
Donors
Family members were assessed for HLA compatibility by serological methods or by highresolution molecular analysis. All donors (20 mothers and two brothers) were identical for one haplotype and incompatible at three loci (HLA-A, -B, -DR) of the other, except for two who were mismatched at two loci (HLA-A, -B) on the unshared haplotype. One brother was mismatched for non-inherited maternal antigens. The stem cell dose was achieved with a median of three leukaphereses (range, 1-5). Twenty-one donors had β -thalassemia minor, one had sickle cell trait.
Ten age-and sex-matched healthy donors were included as control subjects. The control subjects provided bone marrow aspirates, all of which were deemed normal. None of the control subjects had acute infections or were receiving medication at the time of the study. For personal use only. on October 24, 2017. by guest www.bloodjournal.org From
Tests for chimerism
Fluorescent in situ hybridization. When the host and donor were sex mismatched, fluorescent in situ hybridization (FISH) was performed on peripheral blood and bone marrow to detect marrow engraftment 19 .
DNA extraction. High molecular weight DNA was extracted from peripheral blood or bone marrow using a commercial DNA blood mini kit, in accordance with manufacturer's instructions (Qiagen, Hilden, Germany).
Polymerase chain reaction. To evaluate chimerism, four different minisatellite loci (33.6, SE33, APOB, and D1S80) were amplified by polymerase chain reaction (PCR). The PCRamplified products were resolved on precast 10% non-denaturing polyacrylamide gel (NOVEX, San Diego, CA) and the gels were silver stained. Mixed chimerism was estimated semi-quantitatively by comparing recipient and donor band intensities with those of known standards 15 .
Graft Content
Eight patients received T cell-depleted peripheral blood progenitor cells (CD34 anti-CD4-allophycocyanin, anti-CD8-peridinin chlorophyll protein, and anti-CD19-PE were purchased from Becton Dickinson (San Diego, CA, USA).
The NK phenotype of PBMCs was assessed by immunofluorescence and flow cytometry using FITC-conjugated anti-CD3 and PE-conjugated anti-CD56 mAbs (Becton Dickinson).
After staining, cells were washed once in phosphate-buffered saline containing 2% fetal bovine serum and analyzed on a FACSCalibur cytofluorometer (Becton Dickinson, Mountain View, CA, USA) using Cell Quest software. Absolute lymphocyte counts were calculated by standard hemocytometry. To determine marker expression on CD4 + and CD8 + cells, total lymphocytes were first identified and gated by forward and side scatter, then these cells were gated for CD4 or CD8 expression.
Statistical analysis
Estimates of overall survival and event-free survival were calculated by the Kaplan-Meier method 16 . Rejection and non-rejection mortality were calculated as cumulative incidences 17 .
When estimating event-free survival, rejection, recurrence of thalassemia, and death were recorded as events. Rejection was defined as the development of complete marrow aplasia or recurrence of thalassemia (a return to the pre-transplantation pattern of globin-chain synthesis).
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Results
All patients showed donor chimerism by day 14 after HSCT. Granulocytes count greater than 500 /ml occurred after a median time of 13 days (range, [11] [12] [13] [14] [15] [16] [17] .. Six patients rejected their grafts, surviving with thalassemia Three patients showed early mixed chimerism, which became persistent when observed respectively at 14, 38 and 42 months after the transplant.
In 14 cases the transplantation was successful with complete allogeneic reconstitution.. In patients who showed allogeneic reconstitution, median time for granulocyte recovery was 13 days (range, 11-17 days), whereas median time for a self-sustained platelet recovery was 12 days (range,9-17 days). There were 2 patients who died from transplantation-related causes:
one of these patients died on day +114 of Epstein-Barr virus cerebral lymphoma and one died on day +92 for CMV pneumonia. In 6 cases, donor marrow was rejected with complete autologous reconstitution and return to pre-transplant clinical status. In 2 of these patients, Since the first transplant done by our Group in Pesaro on February 15, 1989, 
than 1000 ex-thalassemic after transplant. Their life is normal, this means that they are socially active, the majority has recovered fertility, more and more are having children.
A group working in Pescara has recently published their data 21 None of the children with full as well persistent mixed chimerism developed GVHD ( Figure   1 ).
On day +119, one patient developed varicella zoster meningo-encephalitis (documented by PCR of cerebrospinal fluid) that responded to a combination of acyclovir and foscarnet.
The two drugs were combined because the patient had been receiving acyclovir prophylaxis.
On day +135, this patient also received a donor lymphocyte infusion (5 × Fifteen patients showed CMV infection without disease that resolved with pre-emptive gancyclovir treatment. Three patients had EBV reactivation with a high viral load which resolved after treatment with retuximab.
Immunological reconstitution
Delayed immune reconstitution post transplant may be associated with a variety of functional and immunophenotypic abnormalities at BM level, due to augmented local production of inflammatory cytokines, increased T-cell activation, or intrinsic hematopoietic and stromal cell abnormalities.
At day +20, six of fourteen patients had significantly lower CD4 + T cell counts than did the control subjects (1.9 ± 1.4% vs. 47.5 ± 6%, respectively). The stromal layers cultured on chamber slides were positive for CD68, vimentin, and CD14, but negative for S100 and CD34, indicating cells of macrophage/monocyte lineage 23 .
In the patients with delayed immuno-hematological reconstitution, the majority (80%) of these cells appeared moderately large, rounded, and with abundant cytoplasm on light microscopy. In contrast, about 90% of stromal cells from control subjects were irregular or spindle shaped with branching cytoplasmic processes (fibroblast-like).
Spontaneous stromal cell production of IL-7 was lower in patients than in controls (0.3 ± 0.1 pg/mL vs. 0.8 ± 0.1 pg/mL, respectively; P = .02). After 60 days post transplant, a significant decrease in total lymphocyte counts, and depletion of CD4+ T cells expressing predominantly the CD45RA+CD62L+ phenotype were observed.
Also the CD4+CD45RA+CD31+ T cell subset was significantly reduced in our cohort, suggesting a thymus involvement in these patients. Indeed, it is possible that the T-cell defect in thalassemia patients may occur at multiple levels, including egress from thymus. In conclusion, the transplant protocol described herein, appears to be well tolerated and effective for eradicating the hematopoietic system in patients with thalassemia.
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